Abstract
In the last 15 years, groundbreaking genetic progress has underlined a convergence onto coherent synaptic pathways for most psychiatric and neurodevelopmental disorders, which are now collectively called “synaptopathies.” However, the modest size of inheritance detected so far indicates a multifactorial etiology for these disorders, underlining the key contribution of environmental effects to them. Inflammation is known to influence the risk and/or severity of a variety of synaptopathies. In particular, pro-inflammatory cytokines, produced and released in the brain by activated astrocytes and microglia, may play a pivotal role in these pathologies. Although the link between immune system activation and defects in cognitive processes is nowadays clearly established, the knowledge of the molecular mechanisms by which inflammatory mediators specifically hit synaptic components implicated in synaptopathies is still in its infancy. This review summarizes recent evidence showing that the pro-inflammatory cytokine interleukin-1β (IL-1β) specifically targets synaptopathy molecular substrate, leading to memory defects and pathological processes. In particular, we describe three specific pathways through which IL-1β affects (1) synaptic maintenance/dendritic complexity, (2) spine morphology, and (3) the excitatory/inhibitory balance. We coin the term immune synaptopathies to identify this class of diseases.
Introduction
A large amount of evidence about the genetic architecture of psychiatric and neurodevelopmental diseases has progressively accumulated in the last 15 years or so. The identified pathways typically involve proteins chiefly affecting synapse formation and maintenance, a discovery which has led to the concept of “synaptopathies” (Grant, 2012). The initial excitement raised by these findings has been, however, tempered by the awareness that understanding a given synaptopathy at the level of its genetic, molecular, and synaptic dysfunction is typically insufficient to explain the disease onset, which depends indeed on additional genetic, epigenetic, and environmental factors (; Oh-Nishi et al., 2010; ; Millan, 2013; Giovanoli et al., 2016).
Inflammation is increasingly recognized as a key factor influencing physiology and pathology in the immature and mature brain, which can be exposed to inflammation in connection with viral or bacterial prenatal or postnatal infections or as a result of sterile CNS insults (Hagberg et al., 2015). Extensive research is providing evidence that inflammation has long-term consequences and could speculatively affect the risk and/or severity of a variety of brain diseases, including autism spectrum disorders (ASDs), schizophrenia, and intellectual disabilities (IDs), which represent recognized synaptopathies (Fan et al., 2007; ; Najjar et al., 2013). Accordingly, prenatal and early postnatal infections have been associated with increased risk for a number of neurodevelopmental disorders (; Hagberg et al., 2012; Lipina et al., 2013; Wischhof et al., 2015; Graham et al., 2018).
Pro-inflammatory cytokines, including interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNFα), appear to be at the forefront in the communication between the immune and the nervous system, playing dual roles in mediating physiological and neuroprotective roles in normal brain function (Kushima et al., 1992; Yamada and Hatanaka, 1994; ; Hirota et al., 1996; Wagner, 1996; Gadient and Otten, 1997; Parish et al., 2002; Nakanishi et al., 2007; Heese, 2017) or being detrimental and associated with brain diseases, especially when present at elevated concentrations (Yan et al., 1992; Katila et al., 1994; Gadient and Otten, 1997; Samuelsson et al., 2006; Garay and McAllister, 2010; ; Suzuki et al., 2011; Wei et al., 2011; Erta et al., 2012; ; O’Keeffe, 2017). In particular, experiments performed in rodents have unequivocally demonstrated that inflammation correlates with defective learning and memory paradigms. As an example, influenza infection associated to elevated pro-inflammatory cytokines was found to alter neuronal morphology leading to cognitive impairment in adult mice (Jurgens et al., 2012; Hosseini et al., 2018). Although the link between immune system activation and defects in cognition is solidly established, the molecular underpinnings of this correlation are not completely clear. In particular, the knowledge of whether inflammatory mediators specifically hit synaptic components, previously identified by genetic studies as implicated in synaptopathies, is poor and somehow fragmentary.
Excessive IL-1β Impairs Neuronal Plasticity and Memory
Interleukin-1β is a potent inflammatory cytokine and a fundamental component of the innate immune response (Dinarello, 1996). Besides affecting several organs during inflammatory processes, IL-1β also exerts a number of diverse actions in the central nervous system (CNS) as important mediator of neuronal injury. Twenty years of research have indeed indicated that IL-1β is involved in several brain diseases, including multiple sclerosis (Lin and Edelson, 2017), Alzheimer disease (Griffin et al., 2006), epilepsy (Iori et al., 2016), stroke (Murray et al., 2015), and even neurodevelopmental disorders such as schizophrenia and autism (Soderlund et al., 2009; Girard et al., 2010; Krakowiak et al., 2017).
Despite the heterogeneity of the diseases in which IL-1β is involved, a growing body of evidence points toward a shared physiological process hit by the cytokine: cognition. This concept originally emerged as the result of a series of pioneer experiments showing that the intraperitoneal or intrahippocampal injection of the cytokine results in learning and memory defects (Oitzl et al., 1993; Gibertini et al., 1995; ). The detrimental effects of IL-1β on cognition were later confirmed using transgenic mice expressing the cytokine in an inducible manner (Hein et al., 2010) or upon endogenous IL-1β elevations evoked by infections (Gibertini et al., 1995; ; ), with the memory deficits being prevented, in the latter case, by intraventricular infusion of the naturally occurring interleukin-1 receptor antagonist (IL-1ra; Goshen et al., 2007; ; Frank et al., 2010).
In line with the induction of cognitive defects, excessive IL-1β affects long-term potentiation (LTP), the synaptic process which underlies learning and memory. Indeed, elevated levels of IL-1β inhibit LTP in several regions of the hippocampus, including CA1 (; Ross et al., 2003), CA3 (Katsuki et al., 1990), and dentate gyrus (Murray and Lynch, 1998; Kelly et al., 2003). Of note, the synaptic potentiation processes are not only affected in different pathological scenarios, but also during aging, when the overproduction of IL-1β and/or a synapse-specific IL-1 receptor subunit reconfiguration may produce specific deficits in consolidation of hippocampus-dependent memory (Patterson, 2015; Prieto et al., 2015) and also during stress-related conditions, a particular pathophysiological state which might deeply affect immature brain (; Depino, 2017; Schiavone and Trabace, 2017).
IL-1β Affects Synapse Structure and Function
An extensive series of evidence accumulated over the last 10 years has pointed to the concept that IL-1β directly affects synapse structure and function. Indeed, early experiments performed in primary cultured neurons exposed to recombinant IL-1β revealed a significant decline in the levels of the synaptic vesicle protein synaptophysin (Li et al., 2003) and in the number of synaptic sites (Mishra et al., 2012). The occurrence of deleterious cytokine effects on the synapse structure has been reported in different non-neurological disorders associated to increases of IL-1β levels, like sepsis and obesity, where mice show memory impairment and reduced number of hippocampal and cortical excitatory synapses, through a mechanism fully prevented by the addition of IL-1ra (Erion et al., 2014; Moraes et al., 2015).
Different mechanisms have been called into question to shed light on the association between excessive IL-1β and synaptic alterations, including the modulation of the mitogen-activated protein kinase (MAPK) pathway and the modification of trophic factor production, such as brain-derived neurotrophic factor (BDNF). These processes have been thoroughly analyzed in a previous review (Patterson, 2015). Conversely, it is still unclear whether IL-1β may directly act on neuronal proteins involved in modulating the structure and function of dendritic spines and known to be the molecular targets of synaptopathies. In this review, we will illustrate some recently reported data showing that IL-1β may directly interfere with synaptic processes known to be at the root of neurodevelopmental diseases. The research was performed through PubMed. Inclusion criteria were based on the indicated keywords. Only peer-reviewed original articles and reviews were considered.
IL1RAPL1 and Synapse Stabilization
Interleukin-1-receptor accessory protein like 1 (IL1RAPL1) is a member of the interleukin-1 receptor family. It is selectively expressed in the brain (; ), where it is mainly localized at excitatory synapses. Mutations in the gene encoding for IL1RAPL1 have been found in patients with cognitive impairments ranging from non-syndromic ID to ASD (Ramos-Brossier et al., 2015). Indeed, IL1RAPL1 KO mice display a reduction of spine density in the cortex (Yasumura et al., 2014) and in the CA1 region of the hippocampus (Pavlowsky et al., 2010; Yasumura et al., 2014) and are characterized by altered excitation/inhibition (E/I) balance in the cerebellum and amygdala (Gambino et al., 2009; Houbaert et al., 2013). These molecular and functional alterations are associated with memory deficits (Houbaert et al., 2013; Yasumura et al., 2014). In neurons, IL1RAPL1 plays a role in presynaptic differentiation, in spine formation and stabilization (Pavlowsky et al., 2010; Valnegri et al., 2011; Yoshida et al., 2011; Ramos-Brossier et al., 2015), and in dendritic morphology (Montani et al., 2017). Also IL1RAPL1 C-terminus interacts with the neuronal calcium sensor-1 which regulates voltage-gated calcium channel activity (Gambino et al., 2009). Thus, IL1RAPL1 may promote excitatory synapse formation through two main mechanisms: (i) a trans-synaptic signaling pathway involving the receptor tyrosine phosphatase δ (PTPδ) and RhoGAP2 (Valnegri et al., 2011) and (ii) the control of synaptic localization of PSD-95 through c-Jun N-terminal kinase (JNK) activity and PSD-95 phosphorylation (Pavlowsky et al., 2010).
IL1RAPL1 mediates some of the effects of IL-1β in neurons (Figure 1, pathway 1), controlling, in particular, the cytokine effects on dendritic morphology, possibly through the involvement of JNK pathway (Pavlowsky et al., 2010; Montani et al., 2017). IL1RAPL1 represents therefore the first identified synaptic target of IL-1β. The primary role of the protein in neuronal and synaptic development, together with the observation that IL1RAPL1 is a synaptopathy-related gene, identifies this protein as one of the possible key targets of the immune-to-neuron communication mediated by IL-1β. The future identification of the precise mechanisms by which IL1RAPL1 modulates the activity of IL-1β could offer the opportunity to specifically interfere with the vicious, harmful cycle leading to synapse dysfunction.
FIGURE 1
MeCp2 and Spine “Dysgenesis”
Recent studies have exploited a genetic mouse model of IL-1β deregulation, the IL-1R8 KO mice, as a reliable and reproducible system for examining the effects of inflammation on synapse structure and function, also elucidating the molecular processes involved (; Tomasoni et al., 2017). IL-1R8, also known as single Ig IL-1 related receptor (SIGIRR), reduces the activation of the Toll-like receptors (TLRs; protein sensors for microorganisms and tissue damage) and IL1R signaling pathways by intracellularly interfering with the association of adaptor molecules to the receptor complex including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and JNK, thus leading to upregulation of IL-1 signaling. Mice lacking IL-1R8, previously shown to exhibit LTP deficits (), have been used to investigate the mechanisms through which exaggerated inflammatory conditions impact synapse functions. IL-1R8KO neurons were found to display an increased number of immature, thin spines, and a decreased number of mature, mushroom spines, accompanied by reduction of PSD95 expression and impairment of synaptic plasticity (Tomasoni et al., 2017). The phenotype was rescued by IL-1ra, thus proving the direct involvement of IL-1β signaling (Tomasoni et al., 2017). The structural and functional alterations were found to be causally linked to upregulation of the mammalian target of rapamycin (mTOR) pathway and increased levels of the epigenetic regulator methyl CpG binding protein 2 (MeCP2), which were again normalized by IL-1Ra treatment (Tomasoni et al., 2017). The demonstration that enhanced IL-1β signaling increases the expression of MeCP2, thus negatively impacting synapse function, points to this factor as a potentially fundamental node linking inflammation and synaptic damage (Figure 1, pathway 2). Of note, alterations in the expression of MeCP2 are known to be responsible of neurodevelopmental diseases in humans: sporadic, loss-of-function mutations in the gene coding for MeCP2 result in Rett syndrome (), while a double dosage of MeCP2 causes a severe developmental delay and ID, with even mild over-expression having a robust effect (Delobel et al., 1998; Van Esch et al., 2005). Interestingly, IL-1Ra reduces MeCP2 levels in wild-type neurons which, concomitantly, lose the ability to undergo LTP (Tomasoni et al., 2017). It appears therefore that the effects of IL-1β on neuronal plasticity follow a U-shaped dose–response curve, with levels in either excess or below the physiological range being deleterious to neuronal functions, which is exactly the case of MeCP2, whose levels need to be tightly regulated to guarantee a proper neuronal function (; Lombardi et al., 2015). It will be important to assess whether the IL-1β-mediated modulation of MeCP2 also occurs in humans and to define the molecular mechanisms by which the cytokine modulates MeCP2 levels.
KCC2 and the Excitatory/Inhibitory Balance
Several lines of evidence have highlighted the capacity of IL-1β to promote an imbalance between excitation and inhibition, thus affecting neuronal network excitability. The first indications were obtained in the peripheral nervous system, where elevated levels of pro-inflammatory cytokines, including IL-1β, were found to alter neuronal excitability facilitating pain and hyperalgesia (Viviani et al., 2007; Schafers and Sorkin, 2008). Further studies conducted on the CNS have subsequently demonstrated that high levels of IL-1β, as occurring in neurological disorders such as multiple sclerosis and epilepsy, lead to an E/I imbalance, which might be responsible for – or contribute to – cognitive impairment (Vezzani et al., 2008; Rossi et al., 2012; Iori et al., 2016). Among the possible mechanisms, neuronal network hyperactivity may be the result of an altered excitatory-to-inhibitory switch of GABA signaling, leading to a reduced inhibitory action of GABA (Ganguly et al., 2001; Tyzio et al., 2007; ), a process tightly controlled by the developmentally regulated expression of the two chloride co-transporters, potassium-chloride cotransporter 2 (KCC2) and neuronal Na–K–Cl cotransporter 1 (nKCC1) (; Watanabe and Fukuda, 2015; Raimondo et al., 2017). This evidence raised the question of whether an inflammatory event occurring during brain development may specifically affect this process. Such possibility has been called into question in a recent study, where an immune challenge – consisting in the injection of the viral mimicking molecule polyinosinic–polycytidylic acid (poly I:C) – was delivered to pregnant mice at early stages of embryo development (E9, corresponding to the mid/end of first trimester pregnancy in humans), a model of prenatal infection called maternal immune activation (MIA). The prenatal immune activation resulted in a delay of GABA switch in the offspring, resulting from a higher cortical and hippocampal expression of the transporter nKCC1 and a lower expression of KCC2 compared to controls. The alterations in nKCC1/KCC2 ratio resulted in GABA being excitatory and offspring more susceptible to seizures in the adult stage. The involvement of IL-1β in the process was indicated by the evidence that (i) IL1RKO embryos are protected from this detrimental effect and (ii) IL-1β delays the transition of GABA signaling in cultured neurons (Figure 1, pathway 3; ). Among the transcriptional regulators of KCC2 expression, the neuronal repressor gene RE1-silencing transcription factor (REST) was found to modulate kcc2 gene expression (Yeo et al., 2009) and, in line with this evidence, its binding to KCC2 promoter was enhanced in the brain of offspring exposed to MIA (). However, given that MeCP2 also acts as a transcriptional repressor by binding to the KCC2 gene promoter (Tang et al., 2016), it will be interesting to define the interplay between these two factors and whether the increase of MeCP2 levels induced by IL-1β (Tomasoni et al., 2017) might contribute to KCC2 reduction.
The demonstration that a transient increase of IL-1β during neuronal development may induce long-lasting neuronal network hyperactivity by delaying GABA switch opens unexpected scenarios: impairment of the GABA developmental switch is indeed an important feature of several neurodevelopmental disorders, such as Down syndrome, Rett syndrome, and ASD (Lemonnier et al., 2012; He et al., 2014; Tyzio et al., 2014; ; Inui et al., 2017), for which an important risk factor is represented by prenatal inflammatory conditions (Tarnow-Mordi et al., 2005; Missault et al., 2014).
An E/I imbalance has also been demonstrated in other neurological diseases characterized by excessive IL-1β levels, such as multiple sclerosis and epilepsy. In these cases, alternative molecular mechanisms were found to be involved. In a mouse model of multiple sclerosis, IL-1β-mediated inflammation was found to enhance glutamatergic transmission during the early phase of the disease (; Rossi et al., 2012, 2014; Mandolesi et al., 2013), through modulating vanilloid 1 channels in hippocampus (Rossi et al., 2012), downregulating the glutamate–aspartate transporter/excitatory amino acid transporter 1 (GLAST/EAAT1) in the cerebellum (Mandolesi et al., 2013, 2017), and by activating the apoptotic cascade through p53 activation (Rossi et al., 2014). An IL-1β-dependent enhancement of excitatory neurotransmission has also been reported in epilepsy (Iori et al., 2013) where danger signals such as High Mobility Group Box 1 (HMGB1) and Toll-like receptor 4 (TLR4) were proposed to mediate the IL-1β-dependent increase in neuronal excitability, through an Src kinase-mediated phosphorylation of the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor (Viviani et al., 2003; Maroso et al., 2010, 2011). Together these data indicate that IL-1β disrupts the correct E/I equilibrium acting on multiple molecular targets.
Conclusion and Perspectives
It is now clear that inflammation is an important contributor to defects in brain function, by affecting in particular cognitive processes (Rachal Pugh et al., 2001; Huang and Sheng, 2010; Yirmiya and Goshen, 2011) through concentration-dependent harmful effects induced by the pro-inflammatory cytokine IL-1β. Indeed, recent reports have highlighted the ability of IL-1β to selectively affect cell-to-cell communication in the brain, by targeting specific synaptic pathways (Mishra et al., 2012; Han et al., 2017) which are known to be altered in different synaptopathies (see Figures 1, 2). Among these, IL1RAPL1, MeCP2, and KCC2 are three central molecular players of neurodevelopmental disorders, whose functionality may be affected by IL-1β.
FIGURE 2
These results may have important translational implications. As an example, the recognition that IL-1β modulates MeCP2 levels opens the challenging possibility to target the immune system for treating neurodevelopmental diseases characterized by altered levels of this transcription factor. Observational clinical data already support the possibility to treat cognitive symptoms by immunomodulatory drugs. Indeed, in patients affected by cryopyrin-associated periodic syndrome (CAPS), a group of rare genetic autoinflammatory diseases with levels of IL-1β being fivefold higher than in healthy individuals, symptoms of ID frequently occur. These cognitive defects are reversed following treatment with IL-1Ra () or with specific neutralization of IL-1β with canakinumab (Kuemmerle-Deschner et al., 2011).
Although the modulation of IL-1β signaling in neurology or psychiatry is still in its infancy, the possibility of selectively inhibiting specific steps in the IL-1β cascade may represent a unique opportunity to treat immune synaptopathies (Box 1), i.e., synaptic dysfunctions resulting from deregulation of the immune system during brain development. A control of maternal inflammatory parameters during pregnancy may turn out to be a promising strategy to decrease the incidence of immune-mediated neurological or psychiatric illness in adulthood, as a consequence of maternal viral infections. Specific studies aimed at testing the efficacy of different IL-1β blockers that offer potential benefits to patients in individual disease states will be required in the next future.
Box 1. Synaptopathies and inflammation: the concept of immune-synaptopathies.
The term synaptopathy (from Greek συν, syn – together, απτειν, haptein – to clasp, and παθοϛ, pathos) refers to a class of neurological disorders characterized by alterations at the synaptic level (). The concept of synaptopathy is based on several genetical studies which have identified the involvement, in different diseases, of specific genes whose products converge onto coherent biological pathways controlling various aspects of synaptic structure and function (see Table 1). Besides neurodevelopmental diseases, other brain diseases have been identified as synaptopathies, including neurodegenerative disorders, such as Alzheimer’s (Kerrigan and Randall, 2013) and Parkinson’s (Longhena et al., 2017) diseases. Synaptopathies are therefore defined as resulting from pathological events including synaptic loss (in which synaptic connectivity is compromised), alterations of synaptic functioning (in which the physiological activity of synapses is altered), or both (for a review, see Lepeta et al., 2016). We introduce the novel term immune-synaptopathy to underline the concept that the activation of the immune system, resulting in the formation of soluble immune mediators (i.e., cytokines), which are the main key effectors of the inflammatory response, directly impacts the physiological activity of the synapse producing a disease state (see text for details).
Table 1
| Protein | Gene | Function | Disease (selected) | Reference |
|---|---|---|---|---|
| Complexin-1 | Cplx1 | Transmitter release | HD, SCZ | ; but also Kishi et al., 2006 |
| Complexin-2 | Cplx2 | Transmitter release | HD, SCZ | ; but also Kishi et al., 2006 |
| Munc 18-1 | Stxbp1 | Transmitter release | AD, EPI, PD | Jacobs et al., 2006; Saitsu et al., 2008; |
| SNAP-25 | SNAP25 | Pre and postsynaptic function | ADHD, SCZ, BP, AD | Thompson et al., 1998; Kustanovich et al., 2003; Thapar et al., 2007; Guerini et al., 2014; ; Houenou et al., 2017; Kang et al., 2017 |
| Neurexin-1 | Nrxn1 | Synaptogenesis | ASD, SCZ | Kim et al., 2008; Sudhof, 2008; Vaags et al., 2012 |
| Neuroligin-3 | Nlgn3 | Synaptogenesis | ASD | Jamain et al., 2003; Sudhof, 2008; |
| Neuroligin-4 | Nlgn4 | Synaptogenesis | ASD, ID, TOU | Jamain et al., 2003; Lawson-Yuen et al., 2008; Sudhof, 2008 |
| PSD-95 | Dlg4 | Postsynaptic function | SCZ, ASD | Toro and Deakin, 2005; Kristiansen et al., 2006; Xing et al., 2016 |
| PSD-93 | Dlg2 | Postsynaptic function | SCZ, ASD | Kristiansen et al., 2006; Egger et al., 2014 |
| SAP-102 | Dlg3 | Postsynaptic function | Xlinked ID, SCZ | Oldmeadow et al., 2014; Tzschach et al., 2015; Gieldon et al., 2017 |
| GLUN2B | Grin2B | Receptor function | SCZ, ASD, DEP | Toro and Deakin, 2005; Kristiansen et al., 2006; Zhang et al., 2014 |
| SHANK-3 | Shank3 | Postsynaptic function | ASD | Durand et al., 2007 |
| DISC1 | DISC1 | Synaptogenesis | SCZ | Hayashi-Takagi and Sawa, 2010; Hayashi-Takagi et al., 2010 |
| TNIK | TNiK | Postsynaptic function | SCZ | |
| C4 (complement component 4) | C4 | Synaptic pruning | SCZ | Sekar et al., 2016 |
| MeCP2 | MeCP2 | Regulation of gene expression | Rett | |
| FMRP | FMR1 | Synaptogenesis | FRAXA, ID, ASD | Hagerman and Hagerman, 2004; Hagerman et al., 2004 |
| Gephyrin | GPHN | Receptor function | ASD, EPI | Egger et al., 2014; |
List of selected synaptic and/or synaptic related gene disease.
AD, Alzheimer’s disease; ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; BP, bipolar disorder; DEP, depression; EPI, epilepsy; FRAXA, fragile X syndrome; HD, Huntington’s disease; ID, intellectual disability; SCZ, schizophrenia; TOU, Tourette syndrome; Rett, Rett syndrome; X-link ID, X-linked intellectual disability.
Statements
Author contributions
DP, EM, and MM designed the review outline. All the authors contributed to writing and designing the scheme. CM realized the figure.
Funding
The work in our laboratory was supported by Ministero della Salute GR-2011–02347377, Cariplo 2015–0594, AIRC, Project “AMANDA” CUP_B42F16000440005 from Regione Lombardia and CNR Research Project on Aging and Fondazione Veronesi to MM; Fondazione Vodafone to EM and MM; Cariplo no. 2017-0622 and Progetto Bandiera Interomics 2015–2017 to EM. Cariplo no. 2017-0886 to DP. We thank Monzino Foundation (Milano, Italy) for its generous gift of the Zeiss LSM800 confocal microscope to the section of Milan of the Institute of Neuroscience.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AkaneyaY.TakahashiM.HatanakaH. (1995). Interleukin-1 beta enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons.Exp. Neurol.13644–52. 10.1006/exnr.1995.1082
2
AmirR. E.Van Den VeyverI. B.WanM.TranC. Q.FranckeU.ZoghbiH. Y. (1999). Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.Nat. Genet.23185–188. 10.1038/13810
3
AntonucciF.CorradiniI.FossatiG.TomasoniR.MennaE.MatteoliM. (2016). SNAP-25, a known presynaptic protein with emerging postsynaptic functions.Front. Synaptic Neurosci.8:7. 10.3389/fnsyn.2016.00007
4
AshwoodP.KrakowiakP.Hertz-PicciottoI.HansenR.PessahI.Van De WaterJ. (2011). Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome.Brain Behav. Immun.2540–45. 10.1016/j.bbi.2010.08.003
5
BachoveI.ChangC. (2014). Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes.Open Access Rheumatol.615–25.
6
BarrientosR. M.FrankM. G.HeinA. M.HigginsE. A.WatkinsL. R.RudyJ. W.et al (2009). Time course of hippocampal IL-1 beta and memory consolidation impairments in aging rats following peripheral infection.Brain Behav. Immun.2346–54. 10.1016/j.bbi.2008.07.002
7
BarrientosR. M.HigginsE. A.BiedenkappJ. C.SprungerD. B.Wright-HardestyK. J.WatkinsL. R.et al (2006). Peripheral infection and aging interact to impair hippocampal memory consolidation.Neurobiol. Aging27723–732. 10.1016/j.neurobiolaging.2005.03.010
8
BarrientosR. M.HigginsE. A.SprungerD. B.WatkinsL. R.RudyJ. W.MaierS. F. (2002). Memory for context is impaired by a post context exposure injection of interleukin-1 beta into dorsal hippocampus.Behav. Brain Res.134291–298. 10.1016/S0166-4328(02)00043-8
9
BarronH.HafiziS.AndreazzaA. C.MizrahiR. (2017). Neuroinflammation and oxidative stress in psychosis and psychosis risk.Int. J. Mol. Sci.18:651. 10.3390/ijms18030651
10
BellingerF. P.MadambaS.SigginsG. R. (1993). Interleukin 1 beta inhibits synaptic strength and long-term potentiation in the rat CA1 hippocampus.Brain Res.628227–234. 10.1016/0006-8993(93)90959-Q
11
Ben-AriY.KhalilovI.KahleK. T.CherubiniE. (2012a). The GABA excitatory/inhibitory shift in brain maturation and neurological disorders.Neuroscientist18467–486.
12
Ben-AriY.WoodinM. A.SernagorE.CanceddaL.VinayL.RiveraC.et al (2012b). Refuting the challenges of the developmental shift of polarity of GABA actions: GABA more exciting than ever!Front. Cell. Neurosci.6:35. 10.3389/fncel.2012.00035
13
BeutnerD.FoerstA.Lang-RothR.Von WedelH.WalgerM. (2007). Risk factors for auditory neuropathy/auditory synaptopathy.ORL J. Otorhinolaryngol. Relat. Spec.69239–244. 10.1159/000101545
14
BornT. L.SmithD. E.GarkaK. E.RenshawB. R.BertlesJ. S.SimsJ. E. (2000). Identification and characterization of two members of a novel class of the interleukin-1 receptor (IL-1R) family. Delineation Of a new class of IL-1R-related proteins based on signaling.J. Biol. Chem.27529946–29954. 10.1074/jbc.M004077200
15
BroseN. (2008). Altered complexin expression in psychiatric and neurological disorders: cause or consequence?Mol. Cells257–19.
16
BroseN.O’connorV.SkehelP. (2010). Synaptopathy: dysfunction of synaptic function?Biochem. Soc. Trans.38443–444. 10.1042/BST0380443
17
BrownA. S.DerkitsE. J. (2010). Prenatal infection and schizophrenia: a review of epidemiologic and translational studies.Am. J. Psychiatry167261–280. 10.1176/appi.ajp.2009.09030361
18
BurrowsE. L.LaskarisL.KoyamaL.ChurilovL.BornsteinJ. C.Hill-YardinE. L.et al (2015). A neuroligin-3 mutation implicated in autism causes abnormal aggression and increases repetitive behavior in mice.Mol. Autism6:62. 10.1186/s13229-015-0055-7
19
CarrieA.JunL.BienvenuT.VinetM. C.McdonellN.CouvertP.et al (1999). A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation.Nat. Genet.2325–31. 10.1038/12623
20
CentonzeD.MuzioL.RossiS.CavasinniF.De ChiaraV.BergamiA.et al (2009). Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis.J. Neurosci.293442–3452. 10.1523/JNEUROSCI.5804-08.2009
21
ChaiY. J.SiereckiE.TomatisV. M.GormalR. S.GilesN.MorrowI. C.et al (2016). Munc18-1 is a molecular chaperone for α-synuclein, controlling its self-replicating aggregation.J. Cell Biol.214705–718. 10.1083/jcb.201512016
22
ChaseK. A.ConeJ. J.RosenC.SharmaR. P. (2016). The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia.BMC Psychiatry16:152. 10.1186/s12888-016-0866-x
23
ChenJ.BuchananJ. B.SparkmanN. L.GodboutJ. P.FreundG. G.JohnsonR. W. (2008). Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system.Brain Behav. Immun.22301–311. 10.1016/j.bbi.2007.08.014
24
ChengT. L.QiuZ. (2014). MeCP2: multifaceted roles in gene regulation and neural development.Neurosci. Bull.30601–609. 10.1007/s12264-014-1452-6
25
CobaM. P.KomiyamaN. H.NithianantharajahJ.KopanitsaM. V.IndersmittenT.SkeneN. G.et al (2012). TNiK is required for postsynaptic and nuclear signaling pathways and cognitive function.J. Neurosci.3213987–13999. 10.1523/JNEUROSCI.2433-12.2012
26
CorradiniI.FocchiE.RasileM.MoriniR.DesiatoG.TomasoniR.et al (2017). Maternal immune activation delays excitatory-to-inhibitory gamma-aminobutyric acid switch in offspring.Biol. Psychiatry83680–691. 10.1016/j.biopsych.2017.09.030
27
CostelloD. A.WatsonM. B.CowleyT. R.MurphyN.Murphy RoyalC.GarlandaC.et al (2011). Interleukin-1alpha and HMGB1 mediate hippocampal dysfunction in SIGIRR-deficient mice.J. Neurosci.313871–3879. 10.1523/JNEUROSCI.6676-10.2011
28
DantzerR.O’connorJ. C.FreundG. G.JohnsonR. W.KelleyK. W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain.Nat. Rev. Neurosci.946–56. 10.1038/nrn2297
29
De ChiaraG.MarcocciM. E.SgarbantiR.CivitelliL.RipoliC.PiacentiniR.et al (2012). Infectious agents and neurodegeneration.Mol. Neurobiol.46614–638. 10.1007/s12035-012-8320-7
30
DeiddaG.ParriniM.NaskarS.BozarthI. F.ContestabileA.CanceddaL. (2015). Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome.Nat. Med.21318–326. 10.1038/nm.3827
31
DejanovicB.DjemieT.GrunewaldN.SulsA.KressV.HetschF.et al (2015). Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy.EMBO Mol. Med.71580–1594. 10.15252/emmm.201505323
32
DelobelB.DelannoyV.PiniG.ZapellaM.TardieuM.ValleeL.et al (1998). Identification and molecular characterization of a small 11q23.3 de novo duplication in a patient with Rett syndrome manifestations.Am. J. Med. Genet.80273–280. 10.1002/(SICI)1096-8628(19981116)80:3<273::AID-AJMG19>3.0.CO;2-6
33
DepinoA. M. (2017). Perinatal inflammation and adult psychopathology: from preclinical models to humans.Semin. Cell Dev. Biol.77104–114. 10.1016/j.semcdb.2017.09.010
34
DinarelloC. A. (1996). Biologic basis for interleukin-1 in disease.Blood872095–2147.
35
DurandC. M.BetancurC.BoeckersT. M.BockmannJ.ChasteP.FauchereauF.et al (2007). Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders.Nat. Genet.3925–27. 10.1038/ng1933
36
EggerG.RoetzerK. M.NoorA.LionelA. C.MahmoodH.SchwarzbraunT.et al (2014). Identification of risk genes for autism spectrum disorder through copy number variation analysis in Austrian families.Neurogenetics15117–127. 10.1007/s10048-014-0394-0
37
ErionJ. R.Wosiski-KuhnM.DeyA.HaoS.DavisC. L.PollockN. K.et al (2014). Obesity elicits interleukin 1-mediated deficits in hippocampal synaptic plasticity.J. Neurosci.342618–2631. 10.1523/JNEUROSCI.4200-13.2014
38
ErtaM.QuintanaA.HidalgoJ. (2012). Interleukin-6 a major cytokine in the central nervous system.Int. J. Biol. Sci.81254–1266. 10.7150/ijbs.4679
39
FanX.GoffD. C.HendersonD. C. (2007). Inflammation and schizophrenia.Expert Rev. Neurother.7789–796. 10.1586/14737175.7.7.789
40
FrankM. G.MiguelZ. D.WatkinsL. R.MaierS. F. (2010). Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide.Brain Behav. Immun.2419–30. 10.1016/j.bbi.2009.07.008
41
GadientR. A.OttenU. H. (1997). Interleukin-6 (IL-6)–a molecule with both beneficial and destructive potentials.Prog. Neurobiol.52379–390. 10.1016/S0301-0082(97)00021-X
42
GambinoF.KneibM.PavlowskyA.SkalaH.HeitzS.VitaleN.et al (2009). IL1RAPL1 controls inhibitory networks during cerebellar development in mice.Eur. J. Neurosci.301476–1486. 10.1111/j.1460-9568.2009.06975.x
43
GangulyK.SchinderA. F.WongS. T.PooM. (2001). Gaba itself promotes the developmental switch of neuronal GABAergic responses from excitation to inhibition.Cell105521–532. 10.1016/S0092-8674(01)00341-5
44
GarayP. A.McAllisterA. K. (2010). Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders.Front. Synaptic Neurosci.2:136. 10.3389/fnsyn.2010.00136
45
GardoniF.BorasoM.ZianniE.CorsiniE.GalliC. L.CattabeniF.et al (2011). Distribution of interleukin-1 receptor complex at the synaptic membrane driven by interleukin-1beta and NMDA stimulation.J. Neuroinflammation8:14. 10.1186/1742-2094-8-14
46
GibertiniM.NewtonC.FriedmanH.KleinT. W. (1995). Spatial learning impairment in mice infected with Legionella pneumophila or administered exogenous interleukin-1-beta.Brain Behav. Immun.9113–128. 10.1006/brbi.1995.1012
47
GieldonL.MackenrothL.Betcheva-KrajcirE.RumpA.Beck-WodlS.SchallnerJ.et al (2017). Skewed X-inactivation in a family with DLG3-associated X-linked intellectual disability.Am. J. Med. Genet. A1732545–2550. 10.1002/ajmg.a.38348
48
GiovanoliS.Weber-StadlbauerU.SchedlowskiM.MeyerU.EnglerH. (2016). Prenatal immune activation causes hippocampal synaptic deficits in the absence of overt microglia anomalies.Brain Behav. Immun.5525–38. 10.1016/j.bbi.2015.09.015
49
GirardS.TremblayL.LepageM.SebireG. (2010). IL-1 receptor antagonist protects against placental and neurodevelopmental defects induced by maternal inflammation.J. Immunol.1843997–4005. 10.4049/jimmunol.0903349
50
GoshenI.KreiselT.Ounallah-SaadH.RenbaumP.ZalzsteinY.Ben-HurT.et al (2007). A dual role for interleukin-1 in hippocampal-dependent memory processes.Psychoneuroendocrinology321106–1115. 10.1016/j.psyneuen.2007.09.004
51
GrahamA. M.RasmussenJ. M.RudolphM. D.HeimC. M.GilmoreJ. H.StynerM.et al (2018). Maternal systemic interleukin-6 during pregnancy is associated with newborn amygdala phenotypes and subsequent behavior at 2 years of age.Biol. Psychiatry83109–119. 10.1016/j.biopsych.2017.05.027
52
GrantS. G. (2012). Synaptopathies: diseases of the synaptome.Curr. Opin. Neurobiol.22522–529. 10.1016/j.conb.2012.02.002
53
GriffinW. S.LiuL.LiY.MrakR. E.BargerS. W. (2006). Interleukin-1 mediates Alzheimer and Lewy body pathologies.J. Neuroinflammation3:5.
54
GueriniF. R.AgliardiC.SironiM.ArosioB.CalabreseE.ZanzotteraM.et al (2014). Possible association between SNAP-25 single nucleotide polymorphisms and alterations of categorical fluency and functional MRI parameters in Alzheimer’s disease.J. Alzheimers Dis.421015–1028. 10.3233/JAD-140057
55
HagbergH.GressensP.MallardC. (2012). Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults.Ann. Neurol.71444–457. 10.1002/ana.22620
56
HagbergH.MallardC.FerrieroD. M.VannucciS. J.LevisonS. W.VexlerZ. S.et al (2015). The role of inflammation in perinatal brain injury.Nat. Rev. Neurol.11192–208. 10.1038/nrneurol.2015.13
57
HagermanP. J.HagermanR. J. (2004). Fragile X-associated tremor/ataxia syndrome (FXTAS).Ment. Retard. Dev. Disabil. Res. Rev.1025–30. 10.1002/mrdd.20005
58
HagermanR. J.LeavittB. R.FarzinF.JacquemontS.GrecoC. M.BrunbergJ. A.et al (2004). Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation.Am. J. Hum. Genet.741051–1056. 10.1086/420700
59
HanQ.LinQ.HuangP.ChenM.HuX.FuH.et al (2017). Microglia-derived IL-1β contributes to axon development disorders and synaptic deficit through p38-MAPK signal pathway in septic neonatal rats.J. Neuroinflammation14:52. 10.1186/s12974-017-0805-x
60
Hayashi-TakagiA.SawaA. (2010). Disturbed synaptic connectivity in schizophrenia: convergence of genetic risk factors during neurodevelopment.Brain Res. Bull.83140–146. 10.1016/j.brainresbull.2010.04.007
61
Hayashi-TakagiA.TakakiM.GrazianeN.SeshadriS.MurdochH.DunlopA. J.et al (2010). Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1.Nat. Neurosci.13327–332. 10.1038/nn.2487
62
HeQ.NomuraT.XuJ.ContractorA. (2014). The developmental switch in GABA polarity is delayed in fragile X mice.J. Neurosci.34446–450. 10.1523/JNEUROSCI.4447-13.2014
63
HeeseK. (2017). Functional repertoire of interleukin-6 in the central nervous system - a review.Restor. Neurol. Neurosci.35693–701. 10.3233/RNN-170772
64
HeinA. M.StaskoM. R.MatousekS. B.Scott-MckeanJ. J.MaierS. F.OlschowkaJ. A.et al (2010). Sustained hippocampal IL-1beta overexpression impairs contextual and spatial memory in transgenic mice.Brain Behav. Immun.24243–253. 10.1016/j.bbi.2009.10.002
65
HirotaH.KiyamaH.KishimotoT.TagaT. (1996). Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma.J. Exp. Med.1832627–2634. 10.1084/jem.183.6.2627
66
HosseiniS.WilkE.Michaelsen-PreusseK.GerhauserI.BaumgartnerW.GeffersR.et al (2018). Long-term neuroinflammation induced by influenza A virus infection and the impact on hippocampal neuron morphology and function.J. Neurosci.383060–3080. 10.1523/JNEUROSCI.1740-17.2018
67
HoubaertX.ZhangC. L.GambinoF.LepleuxM.DeshorsM.NormandE.et al (2013). Target-specific vulnerability of excitatory synapses leads to deficits in associative memory in a model of intellectual disorder.J. Neurosci.3313805–13819. 10.1523/JNEUROSCI.1457-13.2013
68
HouenouJ.BoisgontierJ.HenrionA.D’albisM. A.DumaineA.LinkeJ.et al (2017). A multilevel functional study of a SNAP25 at-risk variant for bipolar disorder and schizophrenia.J. Neurosci.3710389–10397. 10.1523/JNEUROSCI.1040-17.2017
69
HuangZ. B.ShengG. Q. (2010). Interleukin-1beta with learning and memory.Neurosci. Bull.26455–468. 10.1007/s12264-010-6023-5
70
InuiT.KumagayaS.Myowa-YamakoshiM. (2017). Neurodevelopmental hypothesis about the etiology of autism spectrum disorders.Front. Hum. Neurosci.11:354. 10.3389/fnhum.2017.00354
71
IoriV.FrigerioF.VezzaniA. (2016). Modulation of neuronal excitability by immune mediators in epilepsy.Curr. Opin. Pharmacol.26118–123. 10.1016/j.coph.2015.11.002
72
IoriV.MarosoM.RizziM.IyerA. M.VertemaraR.CarliM.et al (2013). Receptor for advanced glycation endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures.Neurobiol. Dis.58102–114. 10.1016/j.nbd.2013.03.006
73
JacobsE. H.WilliamsR. J.FrancisP. T. (2006). Cyclin-dependent kinase 5 Munc18a and Munc18-interacting protein 1/X11alpha protein up-regulation in Alzheimer’s disease.Neuroscience138511–522. 10.1016/j.neuroscience.2005.11.017
74
JamainS.QuachH.BetancurC.RastamM.ColineauxC.GillbergI. C.et al (2003). Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism.Nat. Genet.3427–29. 10.1038/ng1136
75
JurgensH. A.AmancherlaK.JohnsonR. W. (2012). Influenza infection induces neuroinflammation, alters hippocampal neuron morphology, and impairs cognition in adult mice.J. Neurosci.323958–3968. 10.1523/JNEUROSCI.6389-11.2012
76
KangQ.ChenJ.YuS.YuanA.ZhangY.ZhangR.et al (2017). Association of the 5-HT2A receptor gene promoter polymorphism-1438G/A with anorexia nervosa and psychopathological traits in the Chinese Han population: a preliminary study.Asia Pac. Psychiatry9. 10.1111/appy.12284
77
KatilaH.AppelbergB.HurmeM.RimonR. (1994). Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders.Schizophr. Res.1229–34. 10.1016/0920-9964(94)90081-7
78
KatsukiH.NakaiS.HiraiY.AkajiK.KisoY.SatohM. (1990). Interleukin-1 beta inhibits long-term potentiation in the CA3 region of mouse hippocampal slices.Eur. J. Pharmacol.181323–326. 10.1016/0014-2999(90)90099-R
79
KellyA.VerekerE.NolanY.BradyM.BarryC.LoscherC. E.et al (2003). Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus.J. Biol. Chem.27819453–19462. 10.1074/jbc.M301938200
80
KerriganT. L.RandallA. D. (2013). A new player in the “synaptopathy” of Alzheimer’s disease - arc/arg 3.1.Front. Neurol.4:9. 10.3389/fneur.2013.00009
81
KimH. G.KishikawaS.HigginsA. W.SeongI. S.DonovanD. J.ShenY.et al (2008). Disruption of neurexin 1 associated with autism spectrum disorder.Am. J. Hum. Genet.82199–207. 10.1016/j.ajhg.2007.09.011
82
KishiT.IkedaM.SuzukiT.KitajimaT.YamanouchiY.KinoshitaY.et al (2006). No association of complexin1 and complexin2 genes with schizophrenia in a Japanese population.Schizophr. Res.82185–189. 10.1016/j.schres.2005.12.842
83
KrakowiakP.GoinesP. E.TancrediD. J.AshwoodP.HansenR. L.Hertz-PicciottoI.et al (2017). Neonatal cytokine profiles associated with autism spectrum disorder.Biol. Psychiatry81442–451. 10.1016/j.biopsych.2015.08.007
84
KristiansenL. V.BeneytoM.HaroutunianV.Meador-WoodruffJ. H. (2006). Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia.Mol. Psychiatry11737–747. 10.1038/sj.mp.4001844
85
Kuemmerle-DeschnerJ. B.RamosE.BlankN.RoeslerJ.FelixS. D.JungT.et al (2011). Canakinumab (ACZ885 a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).Arthritis Res. Ther.13:R34. 10.1186/ar3266
86
KushimaY.HamaT.HatanakaH. (1992). Interleukin-6 as a neurotrophic factor for promoting the survival of cultured catecholaminergic neurons in a chemically defined medium from fetal and postnatal rat midbrains.Neurosci. Res.13267–280. 10.1016/0168-0102(92)90039-F
87
KustanovichV.MerrimanB.McgoughJ.MccrackenJ. T.SmalleyS. L.NelsonS. F. (2003). Biased paternal transmission of SNAP-25 risk alleles in attention-deficit hyperactivity disorder.Mol. Psychiatry8309–315. 10.1038/sj.mp.4001247
88
Lawson-YuenA.SaldivarJ. S.SommerS.PickerJ. (2008). Familial deletion within NLGN4 associated with autism and Tourette syndrome.Eur. J. Hum. Genet.16614–618. 10.1038/sj.ejhg.5202006
89
LemonnierE.DegrezC.PhelepM.TyzioR.JosseF.GrandgeorgeM.et al (2012). A randomised controlled trial of bumetanide in the treatment of autism in children.Transl. Psychiatry2:e202. 10.1038/tp.2012.124
90
LepetaK.LourencoM. V.SchweitzerB. C.Martino AdamiP. V.BanerjeeP.Catuara-SolarzS.et al (2016). Synaptopathies: synaptic dysfunction in neurological disorders - A review from students to students.J. Neurochem.138785–805. 10.1111/jnc.13713
91
LiY.LiuL.BargerS. W.GriffinW. S. (2003). Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway.J. Neurosci.231605–1611.
92
LinC. C.EdelsonB. T. (2017). New insights into the role of IL-1beta in experimental autoimmune encephalomyelitis and multiple sclerosis.J. Immunol.1984553–4560. 10.4049/jimmunol.1700263
93
LipinaT. V.ZaiC.HlousekD.RoderJ. C.WongA. H. (2013). Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice.J. Neurosci.337654–7666. 10.1523/JNEUROSCI.0091-13.2013
94
LombardiL. M.BakerS. A.ZoghbiH. Y. (2015). MECP2 disorders: from the clinic to mice and back.J. Clin. Invest.1252914–2923. 10.1172/JCI78167
95
LonghenaF.FaustiniG.MissaleC.PizziM.SpanoP.BellucciA. (2017). The contribution of alpha-synuclein spreading to Parkinson’s disease synaptopathy.Neural Plast.2017:5012129. 10.1155/2017/5012129
96
MandolesiG.De VitoF.MusellaA.GentileA.BullittaS.FresegnaD.et al (2017). miR-142-3p is a key regulator of IL-1beta-dependent synaptopathy in neuroinflammation.J. Neurosci.37546–561. 10.1523/JNEUROSCI.0851-16.2016
97
MandolesiG.MusellaA.GentileA.GrasselliG.HajiN.SepmanH.et al (2013). Interleukin-1beta alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis.J. Neurosci.3312105–12121. 10.1523/JNEUROSCI.5369-12.2013
98
MarosoM.BalossoS.RavizzaT.LiuJ.AronicaE.IyerA. M.et al (2010). Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures.Nat. Med.16413–419. 10.1038/nm.2127
99
MarosoM.BalossoS.RavizzaT.LiuJ.BianchiM. E.VezzaniA. (2011). Interleukin-1 type 1 receptor/toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1.J. Intern. Med.270319–326. 10.1111/j.1365-2796.2011.02431.x
100
MillanM. J. (2013). An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy.Neuropharmacology682–82. 10.1016/j.neuropharm.2012.11.015
101
MishraA.KimH. J.ShinA. H.ThayerS. A. (2012). Synapse loss induced by interleukin-1β requires pre- and post-synaptic mechanisms.J. Neuroimmune Pharmacol.7571–578. 10.1007/s11481-012-9342-7
102
MissaultS.Van Den EyndeK.Vanden BergheW.FransenE.WeerenA.TimmermansJ. P.et al (2014). The risk for behavioural deficits is determined by the maternal immune response to prenatal immune challenge in a neurodevelopmental model.Brain Behav. Immun.42138–146. 10.1016/j.bbi.2014.06.013
103
MontaniC.Ramos-BrossierM.PonzoniL.GrittiL.CwetschA. W.BraidaD.et al (2017). The X-linked intellectual disability protein IL1RAPL1 regulates dendrite complexity.J. Neurosci.376606–6627. 10.1523/JNEUROSCI.3775-16.2017
104
MoraesC. A.SantosG.De Sampaio e SpohrT. C.D’avilaJ. C.LimaF. R.BenjamimC. F.et al (2015). Activated microglia-induced deficits in excitatory synapses through IL-1β: implications for cognitive impairment in sepsis.Mol. Neurobiol.52653–663. 10.1007/s12035-014-8868-5
105
MurrayC. A.LynchM. A. (1998). Dietary supplementation with vitamin E reverses the age-related deficit in long term potentiation in dentate gyrus.J. Biol. Chem.27312161–12168. 10.1074/jbc.273.20.12161
106
MurrayK. N.Parry-JonesA. R.AllanS. M. (2015). Interleukin-1 and acute brain injury.Front. Cell. Neurosci.9:18. 10.3389/fncel.2015.00018
107
NajjarS.PearlmanD. M.AlperK.NajjarA.DevinskyO. (2013). Neuroinflammation and psychiatric illness.J. Neuroinflammation10:43. 10.1186/1742-2094-10-43
108
NakanishiM.NiidomeT.MatsudaS.AkaikeA.KiharaT.SugimotoH. (2007). Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells.Eur. J. Neurosci.25649–658. 10.1111/j.1460-9568.2007.05309.x
109
Oh-NishiA.ObayashiS.SugiharaI.MinamimotoT.SuharaT. (2010). Maternal immune activation by polyriboinosinic-polyribocytidilic acid injection produces synaptic dysfunction but not neuronal loss in the hippocampus of juvenile rat offspring.Brain Res.1363170–179. 10.1016/j.brainres.2010.09.054
110
OitzlM. S.Van OersH.SchobitzB.De KloetE. R. (1993). Interleukin-1 beta, but not interleukin-6 impairs spatial navigation learning.Brain Res.613160–163. 10.1016/0006-8993(93)90468-3
111
O’KeeffeG. W. (2017). A new role for placental IL-6 signalling in determining neurodevelopmental outcome.Brain Behav. Immun.629–10. 10.1016/j.bbi.2017.02.011
112
OldmeadowC.MossmanD.EvansT. J.HollidayE. G.TooneyP. A.CairnsM. J.et al (2014). Combined analysis of exon splicing and genome wide polymorphism data predict schizophrenia risk loci.J. Psychiatr. Res.5244–49. 10.1016/j.jpsychires.2014.01.011
113
ParishC. L.FinkelsteinD. I.TripanichkulW.SatoskarA. R.DragoJ.HorneM. K. (2002). The role of interleukin-1 interleukin-6 and glia in inducing growth of neuronal terminal arbors in mice.J. Neurosci.228034–8041.
114
PattersonS. L. (2015). Immune dysregulation and cognitive vulnerability in the aging brain: interactions of microglia, IL-1β, BDNF and synaptic plasticity.Neuropharmacology9611–18. 10.1016/j.neuropharm.2014.12.020
115
PavlowskyA.GianfeliceA.PallottoM.ZanchiA.VaraH.KhelfaouiM.et al (2010). A postsynaptic signaling pathway that may account for the cognitive defect due to IL1RAPL1 mutation.Curr. Biol.20103–115. 10.1016/j.cub.2009.12.030
116
PrietoG. A.SnigdhaS.Baglietto-VargasD.SmithE. D.BerchtoldN. C.TongL.et al (2015). Synapse-specific IL-1 receptor subunit reconfiguration augments vulnerability to IL-1β in the aged hippocampus.Proc. Natl. Acad. Sci. U.S.A.112E5078–E5087. 10.1073/pnas.1514486112
117
Rachal PughC.FleshnerM.WatkinsL. R.MaierS. F.RudyJ. W. (2001). The immune system and memory consolidation: a role for the cytokine IL-1beta.Neurosci. Biobehav. Rev.2529–41. 10.1016/S0149-7634(00)00048-8
118
RaimondoJ. V.RichardsB. A.WoodinM. A. (2017). Neuronal chloride and excitability - the big impact of small changes.Curr. Opin. Neurobiol.4335–42. 10.1016/j.conb.2016.11.012
119
Ramos-BrossierM.MontaniC.LebrunN.GrittiL.MartinC.Seminatore-NoleC.et al (2015). Novel IL1RAPL1 mutations associated with intellectual disability impair synaptogenesis.Hum. Mol. Genet.241106–1118. 10.1093/hmg/ddu523
120
RossF. M.AllanS. M.RothwellN. J.VerkhratskyA. (2003). A dual role for interleukin-1 in LTP in mouse hippocampal slices.J. Neuroimmunol.14461–67. 10.1016/j.jneuroim.2003.08.030
121
RossiS.FurlanR.De ChiaraV.MottaC.StuderV.MoriF.et al (2012). Interleukin-1beta causes synaptic hyperexcitability in multiple sclerosis.Ann. Neurol.7176–83. 10.1002/ana.22512
122
RossiS.MottaC.StuderV.MacchiaruloG.VolpeE.BarbieriF.et al (2014). Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53.Mol. Neurodegener.9:56. 10.1186/1750-1326-9-56
123
SaitsuH.KatoM.MizuguchiT.HamadaK.OsakaH.TohyamaJ.et al (2008). De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy.Nat. Genet.40782–788. 10.1038/ng.150
124
SamuelssonA. M.JennischeE.HanssonH. A.HolmangA. (2006). Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning.Am. J. Physiol. Regul. Integr. Comp. Physiol.290R1345–R1356.
125
SchafersM.SorkinL. (2008). Effect of cytokines on neuronal excitability.Neurosci. Lett.437188–193. 10.1016/j.neulet.2008.03.052
126
SchiavoneS.TrabaceL. (2017). Inflammation, stress response, and redox dysregulation biomarkers: clinical outcomes and pharmacological implications for psychosis.Front. Psychiatry8:203. 10.3389/fpsyt.2017.00203
127
SekarA.BialasA. R.De RiveraH.DavisA.HammondT. R.KamitakiN.et al (2016). Schizophrenia risk from complex variation of complement component 4.Nature530177–183. 10.1038/nature16549
128
SoderlundJ.SchroderJ.NordinC.SamuelssonM.Walther-JallowL.KarlssonH.et al (2009). Activation of brain interleukin-1beta in schizophrenia.Mol. Psychiatry141069–1071. 10.1038/mp.2009.52
129
SudhofT. C. (2008). Neuroligins and neurexins link synaptic function to cognitive disease.Nature455903–911. 10.1038/nature07456
130
SuzukiK.MatsuzakiH.IwataK.KamenoY.ShimmuraC.KawaiS.et al (2011). Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders.PLoS One6:e20470. 10.1371/journal.pone.0020470
131
TangX.KimJ.ZhouL.WengertE.ZhangL.WuZ.et al (2016). KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome.Proc. Natl. Acad. Sci. U.S.A.113751–756. 10.1073/pnas.1524013113
132
Tarnow-MordiW.IsaacsD.SmartD. H.StensonB.HaqueK. (2005). Neurodevelopmental impairment and neonatal infections.JAMA293932; author reply 932.
133
ThaparA.LangleyK.OwenM. J.O’donovanM. C. (2007). Advances in genetic findings on attention deficit hyperactivity disorder.Psychol. Med.371681–1692. 10.1017/S0033291707000773
134
ThompsonP. M.SowerA. C.Perrone-BizzozeroN. I. (1998). Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia.Biol. Psychiatry43239–243. 10.1016/S0006-3223(97)00204-7
135
TomasoniR.MoriniR.Lopez-AtalayaJ. P.CorradiniI.CanziA.RasileM.et al (2017). Lack of IL-1R8 in neurons causes hyperactivation of IL-1 receptor pathway and induces MECP2-dependent synaptic defects.Elife6:e21735. 10.7554/eLife.21735
136
ToroC.DeakinJ. F. (2005). NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder.Schizophr. Res.80323–330. 10.1016/j.schres.2005.07.003
137
TyzioR.HolmesG. L.Ben-AriY.KhazipovR. (2007). Timing of the developmental switch in GABA(A) mediated signaling from excitation to inhibition in CA3 rat hippocampus using gramicidin perforated patch and extracellular recordings.Epilepsia48(Suppl. 5), 96–105. 10.1111/j.1528-1167.2007.01295.x
138
TyzioR.NardouR.FerrariD. C.TsintsadzeT.ShahrokhiA.EftekhariS.et al (2014). Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring.Science343675–679. 10.1126/science.1247190
139
TzschachA.GrasshoffU.Beck-WoedlS.DufkeC.BauerC.KehrerM.et al (2015). Next-generation sequencing in X-linked intellectual disability.Eur. J. Hum. Genet.231513–1518. 10.1038/ejhg.2015.5
140
VaagsA. K.LionelA. C.SatoD.GoodenbergerM.SteinQ. P.CurranS.et al (2012). Rare deletions at the neurexin 3 locus in autism spectrum disorder.Am. J. Hum. Genet.90133–141. 10.1016/j.ajhg.2011.11.025
141
ValnegriP.MontrasioC.BrambillaD.KoJ.PassafaroM.SalaC. (2011). The X-linked intellectual disability protein IL1RAPL1 regulates excitatory synapse formation by binding PTPdelta and RhoGAP2.Hum. Mol. Genet.204797–4809. 10.1093/hmg/ddr418
142
Van EschH.BautersM.IgnatiusJ.JansenM.RaynaudM.HollandersK.et al (2005). Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males.Am. J. Hum. Genet.77442–453. 10.1086/444549
143
VezzaniA.BalossoS.RavizzaT. (2008). The role of cytokines in the pathophysiology of epilepsy.Brain Behav. Immun.22797–803. 10.1016/j.bbi.2008.03.009
144
VivianiB.BartesaghiS.GardoniF.VezzaniA.BehrensM. M.BartfaiT.et al (2003). Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases.J. Neurosci.238692–8700.
145
VivianiB.GardoniF.MarinovichM. (2007). Cytokines and neuronal ion channels in health and disease.Int. Rev. Neurobiol.82247–263. 10.1016/S0074-7742(07)82013-7
146
WagnerJ. A. (1996). Is IL-6 both a cytokine and a neurotrophic factor?J. Exp. Med.1832417–2419. 10.1084/jem.183.6.2417
147
WatanabeM.FukudaA. (2015). Development and regulation of chloride homeostasis in the central nervous system.Front. Cell. Neurosci.9:371. 10.3389/fncel.2015.00371
148
WeiH.ZouH.SheikhA. M.MalikM.DobkinC.BrownW. T.et al (2011). IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation.J. Neuroinflammation8:52. 10.1186/1742-2094-8-52
149
WischhofL.IrrsackE.OsorioC.KochM. (2015). Prenatal LPS-exposure–a neurodevelopmental rat model of schizophrenia–differentially affects cognitive functions, myelination and parvalbumin expression in male and female offspring.Prog. Neuropsychopharmacol. Biol. Psychiatry5717–30. 10.1016/j.pnpbp.2014.10.004
150
XingJ.KimuraH.WangC.IshizukaK.KushimaI.AriokaY.et al (2016). Resequencing and association analysis of six PSD-95-related genes as possible susceptibility genes for schizophrenia and autism spectrum disorders.Sci. Rep.6:27491. 10.1038/srep27491
151
YamadaM.HatanakaH. (1994). Interleukin-6 protects cultured rat hippocampal neurons against glutamate-induced cell death.Brain Res.643173–180. 10.1016/0006-8993(94)90023-X
152
YanH. Q.BanosM. A.HerregodtsP.HoogheR.Hooghe-PetersE. L. (1992). Expression of interleukin (IL)-1 beta, IL-6 and their respective receptors in the normal rat brain and after injury.Eur. J. Immunol.222963–2971. 10.1002/eji.1830221131
153
YasumuraM.YoshidaT.YamazakiM.AbeM.NatsumeR.KannoK.et al (2014). IL1RAPL1 knockout mice show spine density decrease, learning deficiency, hyperactivity and reduced anxiety-like behaviours.Sci. Rep.4:6613. 10.1038/srep06613
154
YeoM.BerglundK.AugustineG.LiedtkeW. (2009). Novel repression of Kcc2 transcription by REST-RE-1 controls developmental switch in neuronal chloride.J. Neurosci.2914652–14662. 10.1523/JNEUROSCI.2934-09.2009
155
YirmiyaR.GoshenI. (2011). Immune modulation of learning, memory, neural plasticity and neurogenesis.Brain Behav. Immun.25181–213. 10.1016/j.bbi.2010.10.015
156
YoshidaT.YasumuraM.UemuraT.LeeS. J.RaM.TaguchiR.et al (2011). IL-1 receptor accessory protein-like 1 associated with mental retardation and autism mediates synapse formation by trans-synaptic interaction with protein tyrosine phosphatase delta.J. Neurosci.3113485–13499. 10.1523/JNEUROSCI.2136-11.2011
157
ZhangC.LiZ.WuZ.ChenJ.WangZ.PengD.et al (2014). A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression.Psychopharmacology231685–693. 10.1007/s00213-013-3297-0
Summary
Keywords
synaptopathies, inflammation, cytokines, IL-1β, IL1RAPL1, neurodevelopmental diseases, KCC2, MeCP2
Citation
Pozzi D, Menna E, Canzi A, Desiato G, Mantovani C and Matteoli M (2018) The Communication Between the Immune and Nervous Systems: The Role of IL-1β in Synaptopathies. Front. Mol. Neurosci. 11:111. doi: 10.3389/fnmol.2018.00111
Received
14 January 2018
Accepted
20 March 2018
Published
05 April 2018
Volume
11 - 2018
Edited by
Andras Bilkei-Gorzo, Universität Bonn, Germany
Reviewed by
Luigia Trabace, University of Foggia, Italy; Rommy Von Bernhardi, Pontificia Universidad Católica de Chile, Chile
Updates
Copyright
© 2018 Pozzi, Menna, Canzi, Desiato, Mantovani and Matteoli.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Davide Pozzi, Davide.pozzi@humanitasresearch.it Elisabetta Menna, e.menna@in.cnr.it Michela Matteoli, m.matteoli@in.cnr.it
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.